Region — International. Neutral scientific reference — not offered for sale here.
Explore /
CJC-1295 + Ipamorelin ("CJC/Ipa") Research reference — not for sale
CJC-1295 + Ipamorelin ("CJC/Ipa")
Clead outcome
Synergistic GH release (combination)
grades vary by outcome ↓
Blend / combination⚠ WADA-banned
also called — "CJC/Ipa" · "GHRH + GHRP stack" · GH-secretagogue combination. INCI: none
Research / reference — not for sale. No dosing, reconstitution, or administration is published (intentional). A combination, not a single molecule — and the most-marketed GH-peptide stack with the least combination-specific evidence.
Legal standing, by region
the status of both components applies — placed in 503A Category 2 (2023), status in flux in 2026, not among the July 23–24 2026 PCAC seven, not FDA-approved; not approved in the EU; WADA-prohibited (S2.2).
⚠ WADA-prohibited in sportWADA-prohibited (S2
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Synergistic GH release (combination)
Mechanistically sound, but see below — the specific combo is essentially untested in controlled trials
Mechanistic (GHRH + GHRP synergy is established); each component raises GH in humans · Larger GH pulse than either alone (plausible)
CThe specific CJC-1295 + Ipamorelin combination for any clinical endpoint
Zero combination RCT; anti-aging/body-composition claims are extrapolation
No controlled clinical trial has evaluated it · Not demonstrated
FSafety (combination)
Inherits both components' unknowns; GH/IGF-1 elevation theoretical risks; WADA-banned
No dedicated human safety data · Unknown
—Disclosure
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
Evidence changes
Get notified if this changes
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for CJC-1295 + Ipamorelin ("CJC/Ipa") changes - nothing else.
The honest part
this is the clearest "popularity ≠ evidence" case in the register — the most-marketed GH stack, yet no controlled trial has ever tested the combination. What is known is the pharmacology of each part (they raise GH), not that the stack delivers the outcomes it is sold for.
Identity
a combination of two separate peptides — CJC-1295 (a GHRH-receptor agonist, #16) and Ipamorelin (a GHS-R1a / ghrelin-receptor agonist, #17). Not a single compound.
Rationale
the two act through two different receptors — GHRH-R and the ghrelin receptor — and their signals are complementary, producing a greater GH pulse together than either alone (a long-established GHRH + GHRP synergy in endocrine pharmacology). Neither component meaningfully raises cortisol or prolactin, so the combination is relatively "clean" hormonally. It is the most widely used GH-peptide pairing in functional-medicine and gray-market protocols.
Updated 2026-07-04
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
Region — International
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.